Medications are often used offlabelwhen they are found to have properties or effects that could potentially benefit a disease state or condition they were not originally intended for. Up to one-third of all prescriptions for common medications in the United States are used offlabel.1Glucagon-like peptide1(GLP-1) receptor agonists are a class of medications that were first approved in ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a potent therapeutic option for the management of obesity, demonstrating exceptional efficacy in several large-scale clinical trials. Despite their promising therapeutic outcomes, the rising popularity of these agents raises significant concerns, particularly regarding theiroff-labeluseby individuals seeking weight loss ...
As we can see from the illustration, Glp-1 Analogue Off-Label Uses has many fascinating aspects to explore.
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP1-RAs) and the glucagon-dependent insulinotropic polypeptide (GIP)/GLP1-RA are approved for type 2 diabetes (T2D) and obesity given their profound impact on glycemic weight management.
OFF-LABELAND INVESTIGATIONALUSESOFGLP-1RAS Investigational andoff-labelindications ofGLP1-RAs are conditions that may have some evidence of benefit, but which currently lack FDA approval for a particular medication.
New IQVIA data reveals that more than two-thirds ofGLP-1prescriptions in late 2025 were foroff-labelusesbeyond their FDA-approved indications. Physicians are increasingly prescribing semaglutide and tirzepatide for conditions ranging from PCOS and fatty liver disease to addiction treatment. This shift reflects emerging research onGLP-1receptor agonists' broader metabolic and ...
